Julio Rosenstock, MD, has his work spotlighted as the feature article on the New England Journal of Medicine’s homepage. Serving as the lead investigator for Novo Nordisk’s ONWARDS 1 program, Dr. Rosenstock has made remarkable strides in exploring what could be the world’s first once-weekly basal insulin.
“In ONWARDS 1, insulin icodec allowed people to spend significantly more Time in Range, with comparable Time below Range vs. once-daily basal insulin glargine U100,” said Dr. Rosenstock. “A once-weekly basal insulin has the potential to change how we treat people with type 2 diabetes needing basal insulin replacement.”
Read more about this groundbreaking research and view the accompanying summary video here: https://www.nejm.org/doi/full/10.1056/NEJMoa2303208
